BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7688739)

  • 1. Downstream signal transduction defects that suppress transformation in two revertant cell lines expressing activated rat neu oncogene.
    Reardon DB; Hung MC
    J Biol Chem; 1993 Aug; 268(24):18136-42. PubMed ID: 7688739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
    Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
    J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.
    Lehväslaiho H; Lehtola L; Sistonen L; Alitalo K
    EMBO J; 1989 Jan; 8(1):159-66. PubMed ID: 2565807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of non-ras transforming genes in chemical carcinogenesis.
    Cooper CS
    Environ Health Perspect; 1991 Jun; 93():33-40. PubMed ID: 1685444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repression of neu-induced clonogenicity by dimethylsulfoxide correlates with decreased levels of neu-encoded cell-surface p185 and changes in phosphotyrosine content of endogenous proteins.
    Matin A; Hung MC
    Cancer Lett; 1993 Jan; 68(1):55-60. PubMed ID: 7678546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.
    Stern DF; Kamps MP; Cao H
    Mol Cell Biol; 1988 Sep; 8(9):3969-73. PubMed ID: 2464744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
    Stern DF; Heffernan PA; Weinberg RA
    Mol Cell Biol; 1986 May; 6(5):1729-40. PubMed ID: 2878363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.
    Drebin JA; Link VC; Stern DF; Weinberg RA; Greene MI
    Cell; 1985 Jul; 41(3):697-706. PubMed ID: 2860972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential processing and turnover of the oncogenically activated neu/erb B2 gene product and its normal cellular counterpart.
    Huang SS; Koh HA; Konish Y; Bullock LD; Huang JS
    J Biol Chem; 1990 Feb; 265(6):3340-6. PubMed ID: 1968062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene.
    Yarden Y; Weinberg RA
    Proc Natl Acad Sci U S A; 1989 May; 86(9):3179-83. PubMed ID: 2470093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of cellular platelet-derived growth factor receptors induced by an activated neu receptor tyrosine kinase.
    Lehtola L; Nistér M; Hölttä E; Westermark B; Alitalo K
    Cell Regul; 1991 Aug; 2(8):651-61. PubMed ID: 1685673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells.
    Kamps MP; Sefton BM
    Oncogene Res; 1988 Sep; 3(2):105-15. PubMed ID: 2465525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of protein tyrosine phosphatase 1B expression on transformation by the human neu oncogene.
    Brown-Shimer S; Johnson KA; Hill DE; Bruskin AM
    Cancer Res; 1992 Jan; 52(2):478-82. PubMed ID: 1345814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene.
    Di Marco E; Pierce JH; Knicley CL; Di Fiore PP
    Mol Cell Biol; 1990 Jun; 10(6):3247-52. PubMed ID: 1971420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
    Zhai YF; Beittenmiller H; Wang B; Gould MN; Oakley C; Esselman WJ; Welsch CW
    Cancer Res; 1993 May; 53(10 Suppl):2272-8. PubMed ID: 8097963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene.
    Bargmann CI; Weinberg RA
    Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5394-8. PubMed ID: 2899890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A.
    Yu D; Shi D; Scanlon M; Hung MC
    Cancer Res; 1993 Dec; 53(23):5784-90. PubMed ID: 7902209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppressed autophosphorylation and tyrosine kinase-activity in revertant cell-lines expressing rat Neu oncogene.
    Reardon D; Hung M
    Oncol Rep; 1994 Sep; 1(5):895-902. PubMed ID: 21607462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.
    Bargmann CI; Hung MC; Weinberg RA
    Cell; 1986 Jun; 45(5):649-57. PubMed ID: 2871941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
    Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
    Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.